Table 1.
Baseline patients characteristics.
| Follow-up time, in months | Numbers (%) |
| Median | 60.06 |
| Range | 31.8–79.6 |
| Gender | |
| Male | 9 (100 %) |
| Age, in years | |
| Median | 66 |
| Range | 48–74 |
| Tumor site | |
| Larynx | 8 (89 %) |
| Oropharynx | 1 (11 %) |
| T-stage | |
| T2 | 5 (56 %) |
| T3 | 4 (44 %) |
| N-stage | |
| N0 | 5 (56 %) |
| N1 | 1 (11 %) |
| N2b | 2 (22 %) |
| N2c | 1 (11 %) |
| AJCC stage | |
| II | 3 (33 %) |
| III | 3 (33 %) |
| IV | 3 (33 %) |
| Smoking history | |
| Never | 1 (11 %) |
| >10 pack years | 8 (89 %) |
| Smoking at diagnosis | |
| Yes | 6 (66 %) |
| No | 3 (33 %) |
| Resume smoking after RT | |
| Yes | 2 (22 %) |
| No | 7 (78 %) |
| RT scheme | |
| Accelerated | 4 (44 %) |
| Conventional | 5 (56 %) |
| Dose Olaparib | |
| 25 mg twice a day | 4 (44 %) |
| 25 mg once a day | 5 (56 %) |
Abbreviations: AJCC: American Joint Committee on Cancer; RT: radiotherapy.